BioLine Rx Ltd (NAS:BLRX)
$ 0.2681 -0.0124 (-4.42%) Market Cap: 26.50 Mil Enterprise Value: 28.36 Mil PE Ratio: 0 PB Ratio: 2.44 GF Score: 28/100

BioLine RX Ltd APHEXDA Investor Conference Call Transcript

Sep 12, 2023 / 12:00PM GMT
Release Date Price: $1.99 (-1.97%)
Operator

Good morning, and welcome to the BioLineRx APHEXDA FDA approval conference call. My name is [Yoni Schottenstein], and I will be your operator for today's call. (Operator Instructions)

It is my pleasure to introduce John Lacey, Head of Investor Relations and Corporate Communications at BioLine Rx. John, you may begin the call.

John Lacey
BioLineRx Ltd. - Head of IR and Corporate Communications

Thank you, Yoni. Welcome, everyone, to this morning's call, where we are very pleased to discuss the U.S. Food and Drug Administration's approval of APHEXDA, the trade name for motixafortide.

Joining me today are Phil Serlin, our Chief Executive Officer; Holly May, President of BioLineRx USA; and Beth Giblin, US Head of Medical Affairs. In addition, Ella Sorani, our Chief Development Officer, will be joining the call for Q&A.

I'd like to remind you that certain statements we make during the call will be forward looking. Because such statements deal with future events and are subject to many risks and uncertainties, actual results may

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot